China Biotech Services Achieves First Beam Emission with BNCT Device
China Biotech Services Holdings Ltd. announced that its NeuCure® neutron irradiation system, the core device for boron neutron capture therapy (BNCT) at the Pengbo (Hainan) BNCT Hospital, has successfully performed its first beam emission. This milestone marks the transition of the project from equipment installation to the clinical commissioning phase, verifying that the system's core components meet design specifications. The company stated that the BNCT system is currently the only one in the world with a formal medical device registration certificate and is ready for regular clinical treatment, with related services expected to commence in the first quarter of 2026. These results have just been achieved and announced by the company; they have not yet been presented elsewhere.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Biotech Services Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251125-11928119), on November 25, 2025, and is solely responsible for the information contained therein.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。